A Randomized Phase III Study of SOX [S 1 + oxaliplatin] vs. COX [capecitabine + oxaliplatin] in Patients With Advanced Colorectal Cancer.

Trial Profile

A Randomized Phase III Study of SOX [S 1 + oxaliplatin] vs. COX [capecitabine + oxaliplatin] in Patients With Advanced Colorectal Cancer.

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Jun 2014

At a glance

  • Drugs Gimeracil/oteracil/tegafur (Primary) ; Oxaliplatin (Primary) ; Capecitabine
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Jun 2014 Follow-up results confirming previous primary analysis presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
    • 13 Jun 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
    • 09 Oct 2012 Primary endpoint 'Progression-free-survival-rate' has been met, based on results published in Lancet Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top